Cornedine Jannette de Gooijer, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, gives an overview of the FLORA study, a real-world study assessing the efficacy of second-line platinum-based pemetrexed in patients with pleural mesothelioma, who have progressed on nivolumab and ipilimumab. Whilst this study investigated second line therapies retrospectively, the PEMMELA trial (NCT04287829) prospectively assesses second line treatments in this setting. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Shocked by her diagnosis of mesothelioma and stunned at the limited treatment options available to her, Susan Falbo looked for other options. A combination of two immunotherapeutics shrunk her tumors and improved her quality of life. Learn more at CancerProgressReport.org.

Department of Surgery Grand Rounds
October 16, 2013

Andrea S. Wolf, MD, MPH
Assistant Professor of Cardiothoracic Surgery
Icahn School of Medicine at Mount Sinai

Objectives:

-Understand the rationale for Multimodality Therapy in malignant pleural mesothelioma.
-Discuss gender differences in presentation of malignant pleural mesothelioma and what that may mean for other thoracic cancers.

In June of 2015, Mr. Jerry Bagwell spent two weeks in the hospital due to fluid accumulation around his lung. After the fluid was drained, tests run and biopsy results came back, he finally had a diagnosis: mesothelioma. He and his wife sat down with his doctor in Alabama to come up with a treatment plan. It was at that time that his physician referred him to Dr. David Sugarbaker, a pioneer in the treatment of asbestos related diseases, including mesothelioma. After his initial consultation with Dr. Sugarbaker, Mr. Bagwell agreed to try a radical surgery to attempt to remove the tumor on his lung. Unfortunately his surgery was unsuccessful, but that didn’t stop Mr. Bagwell’s journey. He was recommended to continue treatment for his disease with chemotherapy in his hometown. Nearly a year later, he is feeling well and doing wonderfully.

Dean Fennell, FRCP, PHD, University Hospitals of Leicester NHS Trust, Leicester, UK, provides an overview of the role of immunotherapy in mesothelioma, highlighting the results from CheckMate 743 (NCT02899299) which are now the basis of standard of care in this patient population. The next stages include investigating the potential benefit of chemotherapy and immunotherapy combination approaches as well as implementing precision medicine. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Through complex lung-sparing surgery and an innovative approach to follow-up care, UCLA’s Comprehensive Mesothelioma Program is improving the longevity and quality of life of patients with mesothelioma, a rare and difficult-to-treat cancer that has long been associated with a poor prognosis.

Read more at ucla.in/1ERrdJ1

Mesothelioma often presents in an advanced stage with extensive disease and poor prognosis. In this interview, Kevin Blyth, MBChB, MD, FRCP, University of Glasgow, Glasgow, UK, shares challenges in the diagnosis of mesothelioma, including a lack of specialist tools for quick diagnosis. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.